These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 10495573)

  • 1. [Place of intra-urethral prostaglandin E1 for the treatment of erectile dysfunction].
    Amar E
    Contracept Fertil Sex; 1999; 27(7-8):548-52. PubMed ID: 10495573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Intraurethrally applicated alprostadil for the treatment of organic erectile dysfunction in practice: a multicenter clinical monitoring study (noninterventional investigation)].
    Potempal AJ; Potempa DM; Görlich HD; Stolpmann RM
    Arzneimittelforschung; 2007; 57(6):299-308. PubMed ID: 17688074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale for combination therapy of intraurethral prostaglandin E(1) and sildenafil in the salvage of erectile dysfunction patients desiring noninvasive therapy.
    Nehra A; Blute ML; Barrett DM; Moreland RB
    Int J Impot Res; 2002 Feb; 14 Suppl 1():S38-42. PubMed ID: 11850734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and compliance of MUSE for erectile dysfunction following radical prostatectomy: SHIM (IIEF-5) analysis.
    Raina R; Agarwal A; Zaramo CE; Ausmundson S; Mansour D; Zippe CD
    Int J Impot Res; 2005; 17(1):86-90. PubMed ID: 15526008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MUSE therapy: preliminary clinical observations.
    Werthman P; Rajfer J
    Urology; 1997 Nov; 50(5):809-11. PubMed ID: 9372900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of medications for erectile dysfunction in the United States, 1996 through 2001.
    Wysowski DK; Swann J
    J Urol; 2003 Mar; 169(3):1040-2. PubMed ID: 12576841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of satisfaction rates and erectile function in patients treated with sildenafil, intracavernous prostaglandin E1 and penile implant surgery for erectile dysfunction in urology practice.
    Rajpurkar A; Dhabuwala CB
    J Urol; 2003 Jul; 170(1):159-63. PubMed ID: 12796670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of intraurethral alprostadil in patients not responding to sildenafil citrate.
    Jaffe JS; Antell MR; Greenstein M; Ginsberg PC; Mydlo JH; Harkaway RC
    Urology; 2004 May; 63(5):951-4. PubMed ID: 15134987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term intracavernous therapy responders can potentially switch to sildenafil citrate after radical prostatectomy.
    Raina R; Lakin MM; Agarwal A; Ausmundson S; Montague DK; Zippe CD
    Urology; 2004 Mar; 63(3):532-7; discussion 538. PubMed ID: 15028452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Sildenafil and alprostadil in the combined drug therapy of erectile dysfunction].
    Mazo EB; Dmitriev DG; Gamidov SI; Ovchinnikov RI
    Urologiia; 2002; (3):39-43. PubMed ID: 12180059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newer pharmacologic alternatives for erectile dysfunction.
    Viera AJ; Clenney TL; Shenenberger DW; Green GF
    Am Fam Physician; 1999 Sep; 60(4):1159-66, 1169, 1172. PubMed ID: 10507745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of transurethral application of alprostadil for erectile dysfunction in Indonesians.
    Pangkahila WI
    Asian J Androl; 2000 Sep; 2(3):233-6. PubMed ID: 11225984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy: medicated urethral system for erection enhances sexual satisfaction in sildenafil citrate failure following nerve-sparing radical prostatectomy.
    Raina R; Nandipati KC; Agarwal A; Mansour D; Kaelber DC; Zippe CD
    J Androl; 2005; 26(6):757-60. PubMed ID: 16291971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy.
    Costabile RA; Spevak M; Fishman IJ; Govier FE; Hellstrom WJ; Shabsigh R; Nemo KJ; Rapport JL; Tam PY; Weldon KL; Gesundheit N
    J Urol; 1998 Oct; 160(4):1325-8. PubMed ID: 9751346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment satisfaction in patients with erectile dysfunction switching from prostaglandin E(1) intracavernosal injection therapy to oral sildenafil citrate.
    Montorsi F; Althof SE; Sweeney M; Menchini-Fabris F; Sasso F; Giuliano F
    Int J Impot Res; 2003 Dec; 15(6):444-9. PubMed ID: 14671665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate.
    Israilov S; Niv E; Livne PM; Shmueli J; Engelstein D; Segenreich E; Baniel J
    Int J Impot Res; 2002 Feb; 14(1):38-43. PubMed ID: 11896476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil--a comparative study in 103 patients with erectile dysfunction.
    Porst H
    Int J Impot Res; 1997 Dec; 9(4):187-92. PubMed ID: 9442415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [An evidence-based approach to writing reviews as illustrated by treatment of erectile dysfunction].
    Apolikhin OP; Abdullin II
    Urologiia; 2005; (5):31-5. PubMed ID: 16281837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacological therapy in erectile dysfunction--current standards and new viewpoint].
    Schultheiss D; Stief CG; Truss MC; Jonas U
    Wien Med Wochenschr; 1997; 147(4-5):102-4. PubMed ID: 9190765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Transurethral alprostadil (MUSE) in erectile dysfunction].
    Comeri G; Gianneo E; Nespoli R
    Arch Ital Urol Androl; 1999 Sep; 71(4):249-51. PubMed ID: 10592541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.